Prolia (denosumab) is a prescription drug that’s used to treat osteoporosis and bone loss. Prolia comes as a liquid solution that’s given as an injection under the skin. Prolia is prescribed for ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. In a long-awaited development, the first drug in a new class of ...

Amgen (NASDAQ:AMGN) announced new data supporting its FDA-approved osteoporosis therapy Prolia (Denosumab) on Monday, highlighting its potential against oral alendronate, a commonly-used medication to ...

Continued denosumab treatment is associated with a lower risk for diabetes in adults with osteoporosis older than 65 years, found a large-scale cohort study in Taiwan. Denosumab, used in osteoporosis ...

The surrogate endpoint offers an alternative to traditional fracture endpoints used in clinical trials of osteoporosis drugs ...

The FDA has added a serious warning to the prescribing information for Amgen Inc’s (NASDAQ:AMGN) drug Prolia (denosumab), emphasizing an increased risk of severely low calcium levels in specific ...

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...

The FDA greenlights treatment-related changes in bone mineral density as a surrogate endpoint in anti-osteoporosis drug trials in postmenopausal women.

NEW YORK (Reuters) - The U.S. Food and Drug Administration approved on Tuesday the sale of Amgen Inc's osteoporosis drug Prolia to help prevent fractures in post-menopausal women just days after the ...